ArticleParasites & vectors2022
A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020).
Article in Parasites & vectors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Impact of preventive chemotherapy on Strongyloides stercoralis: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2023Pooled it
- Scrotal filariasis: a case report and clinical considerations.IJID regions · 2026Article
- The influence of human population movement on mass drug administration for neglected tropical diseases: a scoping review.Infectious diseases of poverty · 2026Article
- Progression of lymphatic filariasis antigenaemia and microfilaraemia over 4.5 years in antigen-positive individuals, Samoa 2019-2023.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Article
- Recurrence of microfilaraemia after triple-drug therapy for lymphatic filariasis in Samoa: Recrudescence or reinfection?International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Article
- The effects of variable spatial aggregation on lymphatic filariasis transmission.Parasites & vectors · 2025Article
- Article
- Epidemiology of Lymphatic Filariasis Antigen and Microfilaria in Samoa, 2019: 7-9 Months Post Triple-Drug Mass Administration.Tropical medicine and infectious disease · 2024Article
- Managing Lymphedema Induced by Lymphatic Filariasis: Implementing and Improving Care at the Individual and Programmatic Levels.The American journal of tropical medicine and hygiene · 2024Article
- Narrowing the Gap in Managing the Lymphedema of Lymphatic Filariasis.The American journal of tropical medicine and hygiene · 2024Article
- Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration.PLoS neglected tropical diseases · 2024Article
- The genome of Litomosoides sigmodontis illuminates the origins of Y chromosomes in filarial nematodes.PLoS genetics · 2024Article
- A nationwide epidemiological and geodemographic analysis of lymphatic filariasis in Ecuador: a neglected and often forgotten disease in Ecuador.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundLymphatic filariasis (LF) is a neglected tropical disease (NTD). In 2000 the World Health Organization (WHO) established the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A key component of this programme is mass drug administration (MDA). Between 2000 and 2020, the GPELF has delivered over 8.6 billion treatments to at-risk populations. The last impact assessment of the programme evaluated the treatments provided between 2000-2014. The goal of this analysis is to provide an updated health impact assessment of the programme, based on the numbers treated between 2000-2020.
methodsWe updated and refined a previously established model that estimates the number of clinical manifestations and disability-adjusted life years (DALYs) averted by the treatments provided by the GPELF. The model comprises three different population cohorts that can benefit from MDA provided (those protected from acquiring infection, those with subclinical morbidity prevented from progressing and those with clinical disease alleviated). The treatment numbers were updated for all participating countries using data from the WHO. In addition, data relating to the estimated number of individuals initially at risk of LF infection were updated where possible. Finally, the DALY calculations were refined to use updated disability weights.
resultsUsing the updated model and corresponding treatment data, we projected that the total benefit cohort of the GPELF (2000-2020) would consist of approximately 58.5 million individuals and the programme would avert 44.3 million chronic LF cases. Over the lifetime of the benefit cohorts, this corresponded to 244 million DALYs being averted.
conclusionThis study indicates that substantial health benefits have resulted from the first 20 years of the GPELF. It is important to note that the GPELF would have both additional benefits not quantified by the DALY burden metric as well as benefits on other co-endemic diseases (such as soil-transmitted helminths, onchocerciasis and scabies)-making the total health benefit underestimated. As with the past impact assessments, these results further justify the value and importance of continued investment in the GPELF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.